WallStreetZenWallStreetZen

NASDAQ: MLYS
Mineralys Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MLYS

Based on 5 analysts offering 12 month price targets for Mineralys Therapeutics Inc

Min Forecast
$26.00-28.2%
Avg Forecast
$42.60+17.65%
Max Forecast
$52.00+43.61%

Should I buy or sell MLYS stock?

Based on 5 analysts offering ratings for Mineralys Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
1 analysts 20%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MLYS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MLYS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their MLYS stock forecasts and price targets.

MLYS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-11Find Out Why
lockedlocked$00.00+00.00%2025-09-09
lockedlocked$00.00+00.00%2025-09-08
lockedlocked$00.00+00.00%2025-09-03
lockedlocked$00.00+00.00%2025-08-28Find Out Why

1 of 1

Forecast return on equity

Is MLYS forecast to generate an efficient return?

Company
-21.29%
Industry
131.35%
Market
-50.97%
MLYS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MLYS forecast to generate an efficient return on assets?

Company
-19.88%
Industry
47.84%
MLYS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MLYS earnings per share forecast

What is MLYS's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.83
Avg 2 year Forecast
-$2.83
Avg 3 year Forecast
-$2.56

MLYS revenue forecast

What is MLYS's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$36.6M
Avg 2 year Forecast
$130.7M
Avg 3 year Forecast
$324.3M

MLYS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MLYS$36.21$42.60+17.65%Strong Buy
FOLD$7.73$46.33+499.39%Strong Buy
CPRX$19.76N/AN/A
CELC$55.07$56.50+2.60%Strong Buy
VCYT$31.87$42.00+31.79%Strong Buy
View Top Biotech Stocks

Mineralys Therapeutics Stock Forecast FAQ

Is Mineralys Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: MLYS) stock is to Strong Buy MLYS stock.

Out of 5 analysts, 3 (60%) are recommending MLYS as a Strong Buy, 1 (20%) are recommending MLYS as a Buy, 1 (20%) are recommending MLYS as a Hold, 0 (0%) are recommending MLYS as a Sell, and 0 (0%) are recommending MLYS as a Strong Sell.

If you're new to stock investing, here's how to buy Mineralys Therapeutics stock.

What is MLYS's earnings growth forecast for 2025-2027?

(NASDAQ: MLYS) Mineralys Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.27%.

Mineralys Therapeutics's earnings in 2025 is -$190,773,000.On average, 5 Wall Street analysts forecast MLYS's earnings for 2025 to be -$187,615,371, with the lowest MLYS earnings forecast at -$228,055,433, and the highest MLYS earnings forecast at -$156,456,634. On average, 4 Wall Street analysts forecast MLYS's earnings for 2026 to be -$187,781,109, with the lowest MLYS earnings forecast at -$227,392,481, and the highest MLYS earnings forecast at -$142,534,646.

In 2027, MLYS is forecast to generate -$169,715,671 in earnings, with the lowest earnings forecast at -$198,885,552 and the highest earnings forecast at -$139,219,886.

What is MLYS's revenue growth forecast for 2026-2028?

(NASDAQ: MLYS) Mineralys Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Mineralys Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast MLYS's revenue for 2026 to be $2,427,066,686, with the lowest MLYS revenue forecast at $2,427,066,686, and the highest MLYS revenue forecast at $2,427,066,686. On average, 3 Wall Street analysts forecast MLYS's revenue for 2027 to be $8,661,863,561, with the lowest MLYS revenue forecast at $3,016,430,872, and the highest MLYS revenue forecast at $14,365,503,421.

In 2028, MLYS is forecast to generate $21,502,378,864 in revenue, with the lowest revenue forecast at $8,817,259,472 and the highest revenue forecast at $32,497,899,197.

What is MLYS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MLYS) forecast ROA is -19.88%, which is lower than the forecast US Biotechnology industry average of 47.84%.

What is MLYS's Price Target?

According to 5 Wall Street analysts that have issued a 1 year MLYS price target, the average MLYS price target is $42.60, with the highest MLYS stock price forecast at $52.00 and the lowest MLYS stock price forecast at $26.00.

On average, Wall Street analysts predict that Mineralys Therapeutics's share price could reach $42.60 by Sep 11, 2026. The average Mineralys Therapeutics stock price prediction forecasts a potential upside of 17.65% from the current MLYS share price of $36.21.

What is MLYS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MLYS) Mineralys Therapeutics's current Earnings Per Share (EPS) is -$3.56. On average, analysts forecast that MLYS's EPS will be -$2.83 for 2025, with the lowest EPS forecast at -$3.44, and the highest EPS forecast at -$2.36. On average, analysts forecast that MLYS's EPS will be -$2.83 for 2026, with the lowest EPS forecast at -$3.43, and the highest EPS forecast at -$2.15. In 2027, MLYS's EPS is forecast to hit -$2.56 (min: -$3.00, max: -$2.10).

What is MLYS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MLYS) forecast ROE is -21.29%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.